VI Partners proudly announces its investment into Highlife Medical.

Highlife Medical develops a new 2-component (“valve in ring”) transcatheter mitral valve replacement systems offering unique features for the treatment of mitral valve insufficiency. The transcatheter mitral valve implantation market is regarded as one of the most attractive markets in medical devices and is expected to reach more than 4.6bnUSD in 2027.

VI Partners joins an outstanding syndicate of life science VCs including Sofinnova, Andera, US Ventures and Sectoral Asset Management.